Viking Therapeutics' stock boosted by positive data from trial of treatment for rare metabolic disorder X-ALDMarket Watch • 10/09/24
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALDPRNewsWire • 10/09/24
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street AnalystsThe Motley Fool • 10/07/24
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, PfizerInvestors Business Daily • 10/04/24
Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable RisksSeeking Alpha • 09/25/24
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of DataSeeking Alpha • 09/25/24
Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735The Motley Fool • 09/13/24
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorganBenzinga • 09/11/24